Interestingly, treatment of prostate cancer cells with troglitazone and either a GSK-3β inhibitor (AR-A014418) or GSK-3β siRNA potentiated the effects of troglitazone on suppression of NF-κB activity. The gene discussed is NFKB1; the disease is prostate cancer.